Dr. Atkinson Discusses the COLUMBUS Trial for Melanoma

Video

Victoria Atkinson, MD, medical oncologist, Princess Alexandra Hospital, University of Queensland, discusses the Columbus trial for patients with melanoma.

Victoria Atkinson, MD, medical oncologist, Princess Alexandra Hospital, University of Queensland, discusses the COLUMBUS trial for patients with melanoma.

The COLUMBUS trial investigates the combination of encorafenib and binimetinib. Patients who received encorafenib and binimetinib experienced less photosensitivity and rash, which has been seen with the vemurafenib (Zelboraf) and cobimetinib (Cotellic) compounds, states Atkinson.

The COLUMBUS data are unique since it uses the highest dose of a BRAF inhibitor. This is done in the hopes to have the maximum blockade of the MAP-kinase pathway, explains Atkinson. This trial has seen the longest progression-free survival of targeted therapies.

<<< View more from the World Congress of Melanoma

Related Videos
Patrick I. Borgen, MD
Kari Hacker, MD, PhD, NYU Grossman School of Medicine
Janos L. Tanyi, MD, PhD, associate professor, Obstetrics and Gynecology, Hospital of the University of Pennsylvania
Reshma Lillaney Mahtani, DO
Christian Marth, MD, PhD, head, professor, Department of Obstetrics and Gynecology, Innsbruck Medical University
Mansoor Raza Mirza, MD, chief oncologist, Department of Oncology, Rigshospitalet, Copenhagen University Hospital
Judy Hayek, MD, gynecologic oncology fellow, State University of New York (SUNY) Downstate College of Medicine
Leslie M. Randall, MD, MAS, professor, division head, Department of Obstetrics and Gynecology – Gynecologic Oncology, Virginia Commonwealth University School of Medicine Obstetrics and Gynecology
Dimitrios Nasioudis, MD, fellow, Gynecologic Oncology, Perelman School of Medicine, the University of Pennsylvania
Sara Corvigno, MD, PhD, translational researcher, oncology, The University of Texas MD Anderson Cancer Center